The gold standard treatment for Guillain-Barré Syndrome (GBS) involves immunotherapy, specifically either plasma exchange or intravenous immunoglobulin (IVIg).
Understanding GBS Treatment
Guillain-Barré Syndrome (GBS) is a rare autoimmune disorder in which the immune system attacks the nerves. This can lead to muscle weakness and paralysis. The goal of treatment is to stop the immune system from damaging the nerves and to support the body while it recovers.
Immunotherapy Options
According to available references, two main immunotherapies are considered effective when administered within the first few weeks of the disease:
- Plasma Exchange (PLEX): This procedure removes the patient's plasma, which contains antibodies attacking the nerves, and replaces it with healthy plasma or a plasma substitute.
- Intravenous Immunoglobulin (IVIg): This involves administering high doses of antibodies from healthy donors to help modulate the patient's immune system and reduce the attack on the nerves.
Both treatments are effective for both adults and children.
Treatment Selection
The choice between plasma exchange and IVIg depends on several factors, including:
- Availability of the treatment
- The severity of the GBS
- Patient's overall health
- Potential side effects and risks
